In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
More efficient next-gen obesity clinical trials needed, says survey
In this DDW article, discover key findings of an ICON survey focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
ICON retains lead as most active CRO in Q1, reveals Global Data.
ICON maintains its place as the most active contract research organization (CRO) for Q1 2025.
-
Pharma giants eye obesity trial boom — but are they ready for what comes next?
ICON survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
Shifting paradigms of clinical trial design accelerate CNS R&D
Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed. Bill Holt outlines how drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.
-
Shaping tomorrow: Today’s leaders are building a stronger, more inclusive future for the industry
In this article, Rose Kidd, President of Operational Delivery, discusses how greater support for women in leadership and research is helping to shape a stronger future for the pharma industry.
-
Clinical strategies to optimize software as a medical device to treat mental health
Every clinical trial has challenges, but trials researching SaMD use to treat mental health disorders have unique ethical, regulatory and technical ones. In this Applied Clinical Trials article ICON’s Devin Ridgley and JoAnne Bronikowski explore the implications of a vulnerable patient population and new technology.
-
Navigating protocol development in early phase trials
In an ICON survey of 149 biotech professionals, 45% of survey respondents identified protocol design as one the most significant challenges faced when transitioning from preclinical to clinical testing. Here, we discuss considerations for several key elements of protocol development in early phase trials, including selection of healthy volunteers (HVs) or patients, trial design and endpoint selection.
-
How Global Capability Centers are Shaping the Future of Biometrics
In this interview with India Pharma Outlook, Nagalakshmi Shetty discusses India's emergence as a hub for Global Capability Centres (GCCs), emphasising GCCs' evolution from cost-saving units to innovation-driven strategic centres for global businesses.
-
The rising impact of biomarkers in early clinical development
Dr. Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
-
Grappling with the Grey Zones in EMA Computerised Systems and Electronic Data implementation
The EMA’s Computerised Systems and Electronic Data in Clinical Trials guideline still presents challenges for those seeking EU marketing authorisation. Read our latest regulatory article in IPI magazine to learn more.
